Efficient prime editing in vivo and in vitro using lipid nanoparticles
Source abstract
Abstract
Abstract Prime editing is a versatile clinical genome editing method that enables precise substitutions, small insertions and deletions at specified locations in the genomes of living systems including human cells. Although non-viral lipid nanoparticle (LNP) delivery of RNA in vivo has become a preferred method for gene editing in animals and patients, its application to complex, three-component prime editing systems has yielded low editing efficiencies. Here we developed a systematic prime editing LNP (PE-LNP) optimization platform that addresses key bottlenecks in cargo design that limit editing efficiency. This generalizable workflow yielded PE-LNPs that can achieve 49% average in vivo prime editing in the bulk mouse liver with a single dose of 2 mg kg −1 . We applied our workflow to the correction of PAH R408W, a cause of phenylketonuria, in a mouse model and achieved prime editing efficiencies and serum phenylalanine levels anticipated to be curative. We also show that PE-LNPs minimize off-target editing compared with DNA delivery methods, induce only transient elevation of liver enzymes and can be dosed repeatedly to improve editing efficiencies. These PE-LNP systems provide an attractive alternative to viral delivery by offering transient expression that minimizes off-target editing, no observed long-term toxicity and high levels of non-viral in vivo liver prime editing.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: CRISPR and Genetic Engineering · RNA regulation and disease · Biotin and Related Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (69)
Show source-provided references
1. Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149–157 (2019).10.1038/s41586-019-1711-4 ↗
2. Heath, J. M. et al. Prime editing efficiently and precisely corrects causative mutation in chronic granulomatous disease, restoring myeloid function: toward development of a prime edited autologous hematopoietic stem cell therapy. Blood 142, 7129–7129 (2023).10.1182/blood-2023-186365 ↗
3. Everette, K. A. et al. Ex vivo prime editing of patient haematopoietic stem cells rescues sickle-cell disease phenotypes after engraftment in mice. Nat. Biomed. Eng. 7, 616–628 (2023).10.1038/s41551-023-01026-0 ↗
4. Li, C. et al. In vivo HSC prime editing rescues sickle cell disease in a mouse model. Blood 141, 2085–2099 (2023).
5. Sousa, A. A. et al. In vivo prime editing rescues alternating hemiplegia of childhood in mice. Cell 188, 4275–4294 (2025).10.1016/j.cell.2025.06.038 ↗
6. Qin, H. et al. Vision rescue via unconstrained in vivo prime editing in degenerating neural retinas. J. Exp. Med. 220, e20220776 (2023).10.1084/jem.20220776 ↗
7. Fu, Y. et al. In vivo prime editing rescues photoreceptor degeneration in nonsense mutant retinitis pigmentosa. Nat. Commun. 16, 2394 (2025).10.1038/s41467-025-57628-6 ↗
8. Jang, H. et al. Application of prime editing to the correction of mutations and phenotypes in adult mice with liver and eye diseases. Nat. Biomed. Eng. 6, 181–194 (2021).10.1038/s41551-021-00788-9 ↗
9. An, M. et al. Engineered virus-like particles for transient delivery of prime editor ribonucleoprotein complexes in vivo. Nat. Biotechnol. 42, 1526–1537 (2024).10.1038/s41587-023-02078-y ↗
10. Brooks, D. L. et al. Efficient in vivo prime editing corrects the most frequent phenylketonuria variant, associated with high unmet medical need. Am. J. Hum. Genet. 110, 2003–2014 (2023).10.1016/j.ajhg.2023.10.005 ↗
11. Böck, D. et al. In vivo prime editing of a metabolic liver disease in mice. Sci. Transl. Med. 14, eabl9238 (2022).10.1126/scitranslmed.abl9238 ↗
12. Rothgangl, T. et al. Treatment of a metabolic liver disease in mice with a transient prime editing approach. Nat. Biomed. Eng. 9, 1705–1718 (2025).10.1038/s41551-025-01399-4 ↗
13. Liu, P. et al. Improved prime editors enable pathogenic allele correction and cancer modelling in adult mice. Nat. Commun. 12, 2121 (2021).10.1038/s41467-021-22295-w ↗
14. Gillmore, J. D. et al. CRISPR–Cas9 in vivo gene editing for transthyretin amyloidosis. N. Engl. J. Med. 385, 493–502 (2021).10.1056/NEJMoa2107454 ↗
15. Musunuru, K. et al. Patient-specific in vivo gene editing to treat a rare genetic disease. N. Engl. J. Med. 392, 2235–2243 (2025).10.1056/NEJMoa2504747 ↗
16. Beam Therapeutics. Beam Therapeutics presents additional data for BEAM-302 in alpha-1 antitrypsin deficiency (AATD). In 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-presents-additional-data-beam-302-alpha-1 (2025).
17. Musunuru, K. et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature 593, 429–434 (2021).10.1038/s41586-021-03534-y ↗
18. Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078–1094 (2021).10.1038/s41578-021-00358-0 ↗
19. Paunovska, K., Loughrey, D. & Dahlman, J. E. Drug delivery systems for RNA therapeutics. Nat. Rev. Genet. 23, 265–280 (2022).10.1038/s41576-021-00439-4 ↗
20. Hosseini-Kharat, M., Bremmell, K. E. & Prestidge, C. A. Why do lipid nanoparticles target the liver? Understanding of biodistribution and liver-specific tropism. Mol. Ther. Methods Clin. Dev. 33, 101436 (2025).10.1016/j.omtm.2025.101436 ↗
21. Akinc, A. et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 18, 1357–1364 (2010).10.1038/mt.2010.85 ↗
22. Chen, Z. et al. In vivo prime editing by lipid nanoparticle co-delivery of chemically modified pegRNA and prime editor mRNA. GEN Biotechnol. 2, 490–502 (2023).10.1089/genbio.2023.0045 ↗
23. Liu, P. et al. Increasing intracellular dNTP levels improves prime editing efficiency. Nat. Biotechnol. 43, 539–544 (2024).10.1038/s41587-024-02405-x ↗
24. Nelson, J. W. et al. Engineered pegRNAs improve prime editing efficiency. Nat. Biotechnol. 40, 402–410 (2021).10.1038/s41587-021-01039-7 ↗
25. Yan, J. et al. Improving prime editing with an endogenous small RNA-binding protein. Nature 628, 639–647 (2024).10.1038/s41586-024-07259-6 ↗
26. Doman, J. L. et al. Phage-assisted evolution and protein engineering yield compact, efficient prime editors. Cell 186, 3983–4002 (2023).10.1016/j.cell.2023.07.039 ↗
27. Sakai, H. A. et al. Directed evolution of small RNA-stabilizing motifs that improve prime editing. Nat. Biotechnol. https://doi.org/10.1038/s41587-026-03123-2 (2026).10.1038/s41587-026-03123-2 ↗
28. Fenton, O. S. et al. Bioinspired alkenyl amino alcohol ionizable lipid materials for highly potent in vivo mRNA delivery. Adv. Mater. 28, 2939–2943 (2016).10.1002/adma.201505822 ↗
29. Herrera-Barrera, M. et al. Lipid nanoparticle-enabled intracellular delivery of prime editors. AAPS J. 25, 65 (2023).10.1208/s12248-023-00833-2 ↗
30. Davis, K. M., Pattanayak, V., Thompson, D. B., Zuris, J. A. & Liu, D. R. Small molecule–triggered Cas9 protein with improved genome-editing specificity. Nat. Chem. Biol. 11, 316–318 (2015).10.1038/nchembio.1793 ↗
31. Zuris, J. A. et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat. Biotechnol. 33, 73–80 (2014).10.1038/nbt.3081 ↗
32. Rees, H. A. et al. Improving the DNA specificity and applicability of base editing through protein engineering and protein delivery. Nat. Commun. 8, 15790 (2017).10.1038/ncomms15790 ↗
33. Banskota, S. et al. Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. Cell 185, 250–265 (2022).10.1016/j.cell.2021.12.021 ↗
34. Li, S. et al. Payload distribution and capacity of mRNA lipid nanoparticles. Nat. Commun. 13, 5561 (2022).10.1038/s41467-022-33157-4 ↗
35. Shuto, Y. et al. Structural basis for pegRNA-guided reverse transcription by a prime editor. Nature 631, 224–231 (2024).10.1038/s41586-024-07497-8 ↗
36. Zhang, W. et al. Enhancing CRISPR prime editing by reducing misfolded pegRNA interactions. Elife 12, RP90948 (2024).10.7554/eLife.90948.2 ↗
37. Baiersdörfer, M. et al. A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA. Mol. Ther. Nucleic Acids 15, 26–35 (2019).10.1016/j.omtn.2019.02.018 ↗
38. Chatterjee, S., Kon, E., Sharma, P. & Peer, D. Endosomal escape: a bottleneck for LNP-mediated therapeutics. Proc. Natl Acad. Sci. USA 121, e2307800120 (2024).10.1073/pnas.2307800120 ↗
39. Hassett, K. J. et al. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol. Ther. Nucleic Acids 15, 1–11 (2019).10.1016/j.omtn.2019.01.013 ↗
40. Jayaraman, M. et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in Vivo. Angew. Chem. Int. Ed. 51, 8529–8533 (2012).10.1002/anie.201203263 ↗
41. Cheng, M. H. Y. et al. Induction of bleb structures in lipid nanoparticle formulations of mRNA leads to improved transfection potency. Adv. Mater. 35, 2303370 (2023).10.1002/adma.202303370 ↗
42. Finn, J. D. et al. A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep. 22, 2227–2235 (2018).10.1016/j.celrep.2018.02.014 ↗
43. Li, L. et al. Glucocorticoid pre-administration improves LNP-mRNA mediated protein replacement and genome editing therapies. Int. J. Pharm. 672, 125282 (2025).10.1016/j.ijpharm.2025.125282 ↗
44. Andries, O. et al. N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J. Control. Release 217, 337–344 (2015).10.1016/j.jconrel.2015.08.051 ↗
45. Brooks, D. L. et al. A base editing strategy using mRNA-LNPs for in vivo correction of the most frequent phenylketonuria variant. Hum. Genet. Genom. Adv. 5, 100253 (2024).10.1016/j.xhgg.2023.100253 ↗
46. Lee, R. G. et al. Efficacy and safety of an investigational single-course CRISPR base-editing therapy targeting PCSK9 in nonhuman primate and mouse models. Circulation 147, 242–253 (2023).10.1161/CIRCULATIONAHA.122.062132 ↗
47. Hillert, A. et al. The genetic landscape and epidemiology of phenylketonuria. Am. J. Hum. Genet. 107, 234–250 (2020).10.1016/j.ajhg.2020.06.006 ↗
48. van Spronsen, F. J. et al. Phenylketonuria. Nat. Rev. Dis. Primers 7, 36 (2021).10.1038/s41572-021-00267-0 ↗
49. Vockley, J. et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet. Med. 16, 188–200 (2014).10.1038/gim.2013.157 ↗
50. Kim, S., Kim, D., Cho, S. W., Kim, J. & Kim, J.-S. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 24, 1012–1019 (2014).10.1101/gr.171322.113 ↗
51. Ramakrishna, S. et al. Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. Genome Res. 24, 1020–1027 (2014).10.1101/gr.171264.113 ↗
52. Cameron, P. et al. Mapping the genomic landscape of CRISPR–Cas9 cleavage. Nat. Methods 14, 600–606 (2017).10.1038/nmeth.4284 ↗
53. Lattanzi, A. et al. Optimization of CRISPR/Cas9 delivery to human hematopoietic stem and progenitor cells for therapeutic genomic rearrangements. Mol. Ther. 27, 137–150 (2019).10.1016/j.ymthe.2018.10.008 ↗
54. Tsai, S. Q. et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR–Cas nucleases. Nat. Biotechnol. 33, 187–197 (2014).10.1038/nbt.3117 ↗
55. Davis, J. R. et al. Efficient prime editing in mouse brain, liver and heart with dual AAVs. Nat. Biotechnol. 42, 253–264 (2023).10.1038/s41587-023-01758-z ↗
56. Bish, L. T. et al. Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum. Gene Ther. 19, 1359–1368 (2008).10.1089/hum.2008.123 ↗
57. Habib, O., Habib, G., Hwang, G.-H. & Bae, S. Comprehensive analysis of prime editing outcomes in human embryonic stem cells. Nucleic Acids Res. 50, 1187–1197 (2022).10.1093/nar/gkab1295 ↗
58. Gao, R. et al. Genomic and Transcriptomic analyses of prime editing guide RNA–independent off-target effects by prime editors. CRISPR J. 5, 276–293 (2022).10.1089/crispr.2021.0080 ↗
59. Liang, S.-Q. et al. Genome-wide profiling of prime editor off-target sites in vitro and in vivo using PE-tag. Nat. Methods 20, 898–907 (2023).10.1038/s41592-023-01859-2 ↗
60. Fiumara, M. et al. Author Correction: Genotoxic effects of base and prime editing in human hematopoietic stem cells. Nat. Biotechnol. 42, 986–986 (2024).10.1038/s41587-024-02142-1 ↗
61. Kim, D. Y., Moon, S. B., Ko, J.-H., Kim, Y.-S. & Kim, D. Unbiased investigation of specificities of prime editing systems in human cells. Nucleic Acids Res. 48, 10576–10589 (2020).10.1093/nar/gkaa764 ↗
62. Zhang, H. et al. Algorithm for optimized mRNA design improves stability and immunogenicity. Nature 621, 396–403 (2023).10.1038/s41586-023-06127-z ↗
63. Chen, H. et al. Chemical and topological design of multicapped mRNA and capped circular RNA to augment translation. Nat. Biotechnol. 43, 1128–1143 (2024).10.1038/s41587-024-02393-y ↗
64. Chen, H. et al. Branched chemically modified poly(A) tails enhance the translation capacity of mRNA. Nat. Biotechnol. 43, 194–203 (2024).10.1038/s41587-024-02174-7 ↗
65. Lei, X. et al. Rapid generation of long, chemically modified pegRNAs for prime editing. Nat. Biotechnol. 43, 1156–1167 (2024).10.1038/s41587-024-02394-x ↗
66. Ryan, D. E. et al. Phosphonoacetate modifications enhance the stability and editing yields of guide RNAs for Cas9 editors. Biochemistry 62, 3512–3520 (2022).10.1021/acs.biochem.1c00768 ↗
67. Yin, H. et al. Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing. Nat. Biotechnol. 35, 1179–1187 (2017).10.1038/nbt.4005 ↗
68. Chen, D. et al. Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation. J. Am. Chem. Soc. 134, 6948–6951 (2012).10.1021/ja301621z ↗
69. Ma, Y., VanKeulen-Miller, R. & Fenton, O. S. mRNA lipid nanoparticle formulation, characterization and evaluation. Nat. Protoc. 20, 2618–2651 (2025).10.1038/s41596-024-01134-4 ↗